Patents by Inventor Charles B. Simone

Charles B. Simone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260021325
    Abstract: Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue involves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined, multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, provided are methods which utilize the highest energy layer and a universal range shifter (URS) to facilitate rapid spot arc therapy (RAPIDSPARCâ„¢).
    Type: Application
    Filed: July 18, 2025
    Publication date: January 22, 2026
    Applicant: The New York Proton Center
    Inventors: Minglei KANG, Shouyi WEI, J. Isabelle CHOI, Haibo LIN, Charles B. SIMONE
  • Publication number: 20260021326
    Abstract: Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue involves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined; multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, provided are methods which utilize the highest energy layer and a universal range shifter (URS) to facilitate rapid spot arc therapy (RAPIDSPARCâ„¢).
    Type: Application
    Filed: July 18, 2025
    Publication date: January 22, 2026
    Applicant: The New York Proton Center
    Inventors: Minglei KANG, Xingyi ZHAO, J. Isabelle CHOI, Haibo LIN, Charles B. SIMONE
  • Publication number: 20220323791
    Abstract: Disclosed herein are cancer treatment methods.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 13, 2022
    Applicant: The New York Proton Center
    Inventors: Minglei Kang, Shouyi Wei, J. Isabelle Choi, Haibo Lin, Charles B. Simone
  • Patent number: 7319970
    Abstract: An automatic health and lifestyle analysis computer system is provided, which surveys individual respondents and provides insurability estimates and cost evaluations based upon answers to the surveys.
    Type: Grant
    Filed: February 22, 1996
    Date of Patent: January 15, 2008
    Inventor: Charles B. Simone
  • Patent number: 5397786
    Abstract: A liquid composition to be used as a rehydration drink, particularly suited for the administration to people who do heavy work under severe conditions, e.g. at high temperatures, and to sportspeople and athletes, as well as to patients who exhibit dehydration symptoms due to severe illnesses such as diarrhea or vomiting, contains per serving unit water at least 1 to 100 g of at least one carbohydrate, such as glucose polymers, maltodextrin and fructose; 2 to 2500 mg of at least one electrolyte, such as an alkali and/or earth alkali salt; 0,1 to 750 mg of at least one ammonia neutralizer, such as D,L-magnesium aspartate, L-arginine and glutamate; at least one energy enhancer, such as members of the vitamin B group and branched chain amino acids; at least one antioxidant such as .beta.-carotene, vitamin C, vitamin E and selenium; 1 to 30 mg of at least one membrane stabilizer, such as choline chloride, betaine chloride and methionine; and 1 to 200 .mu.
    Type: Grant
    Filed: January 8, 1993
    Date of Patent: March 14, 1995
    Inventor: Charles B. Simone